USPTO Art Unit 1621 Prosecution Statistics

Art Unit Information

Art Unit: 1621
Group: 1620
Tech Center: 1600
Total Cases: 21,724
Last Active: February 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19054180GLP-1R AGONIST COMPOUND AND USE THEREOFFebruary 2025June 2025Allow410YesNo
19020085INHIBITORS OF KIF18A AND USES THEREOFJanuary 2025June 2025Allow501NoNo
18980700THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAFDecember 2024June 2025Allow710NoNo
18977370SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTIONDecember 2024April 2025Allow410NoNo
18968101SUBSTITUTED PHENYL OXAZOLONE COMPOUNDSDecember 2024April 2025Allow510NoNo
18951509PLEUROMUTILIN ONIUM SALT DERIVATIVE CONTAINING A 3H-IMIDAZO[4,5-C]PYRIDINE SIDE CHAIN, AND A PREPARATION METHOD AND APPLICATION THEREOFNovember 2024January 2025Allow210NoNo
18946234FORMULATION PRODUCTION PROCESSNovember 2024June 2025Allow720YesNo
18938926CABOZANTINIB COMPOSITIONS AND METHODS OF USENovember 2024May 2025Allow611NoNo
18914691ARYL-1,2,3-TRIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR TREATMENT OF BREAST CANCEROctober 2024January 2025Allow310NoNo
18854563RUTHENIUM PRECURSOR COMPOSITION, PREPARATION METHOD THEREFOR, AND FORMATION METHOD FOR RUTHENIUM-CONTAINING FILM USING SAMEOctober 2024February 2025Allow400NoNo
18884965GLP-1R Agonist and Therapeutic Method ThereofSeptember 2024November 2024Allow200NoNo
18823214PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFORSeptember 2024March 2025Allow601NoNo
18812060TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCERAugust 2024December 2024Allow400YesNo
18805490COMPOUNDS AS INHIBITORS OF AXLAugust 2024September 2024Allow100NoNo
18782879CRYSTALLINE FORMS OF A KRAS G12C INHIBITORJuly 2024December 2024Allow510YesNo
18764540MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USESJuly 2024May 2025Allow1101YesNo
18764277LASOFOXIFENE TREATMENT OF AROMATASE-RESISTANT ER+ CANCERJuly 2024December 2024Allow610YesNo
18763302COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOFJuly 2024March 2025Abandon810NoNo
18763210PYRIDO-[3,4-d]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 INHIBITORSJuly 2024September 2024Allow210NoNo
18762532HETEROCYCLIC GLP-1 AGONISTSJuly 2024August 2024Allow200NoNo
18755058PCNA INHIBITORSJune 2024July 2025Allow1210NoNo
18754049NONIONIC POLYETHER SURFACTANTSJune 2024June 2025Allow1110NoNo
18676679POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTSMay 2024January 2025Allow821YesNo
18670566METHOD OF TREATMENT AND SELECTION OF PATIENTS BENEFITING FROM AGOMELATINE BASED ON EEG MEASUREMENTSMay 2024January 2025Allow820YesNo
18669184TRICYCLIC JANUS KINASE 1 INHIBITORS, AND COMPOSITIONS AND METHODS THEREOFMay 2024June 2025Abandon1310NoNo
18663952PRMT5 INHIBITORS AND USES THEREOFMay 2024February 2025Allow911NoNo
18659715Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune DisordersMay 2024April 2025Allow1101YesNo
18655062THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERSMay 2024March 2025Allow1011YesNo
18706706METHODS FOR PREPARING DIHYDROXYAMMONIUM 5,5'-BISTETRAZOLE-1,1'DIOLATEMay 2024January 2025Allow910NoNo
18651214FIVE-MEMBERED RING-FUSED SIX-MEMBERED RING COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOFApril 2024March 2025Allow1111NoNo
18646687THIOAMIDE DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOFApril 2024October 2024Allow610NoNo
18644945TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORSApril 2024May 2025Allow1300NoNo
18645315GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOFApril 2024July 2024Allow300YesNo
187024855 ALPHA DIHYDROTESTOSTERONE FORMULATIONS AND ASSOCIATED METHODS OF USE AND TREATMENTApril 2024March 2025Allow1130YesNo
18636731AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORSApril 2024February 2025Allow1000NoNo
18635402INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7)April 2024May 2025Abandon1310NoNo
18634599IMIDAZOTRIAZINE THIOBENZAMIDE DERIVATIVE, AND PREPARATION METHOD AND APPLICATION THEREOFApril 2024November 2024Allow710NoNo
18628424PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASEApril 2024September 2024Allow610NoNo
18626740COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASEApril 2024March 2025Allow1111YesNo
186251302-(BENZO[D]OXAZOL-2-YL)-N'-(3,5-DICHLOROBENZOYLOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDApril 2024July 2024Allow300YesNo
18618379SALT OF AN AMINOPYRIDINE DERIVATIVE COMPOUND, A CRYSTALLINE FORM THEREOF, AND A PROCESS FOR PREPARING THE SAMEMarch 2024July 2025Allow1521YesNo
18617723NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERSMarch 2024April 2025Allow1301NoNo
18617266APOL1 INHIBITORS AND METHODS OF USEMarch 2024February 2025Allow1110NoNo
18612849COMPOUNDS AND THEIR USEMarch 2024April 2025Allow1301NoNo
18610041AZAINDOLE ROCK INHIBITORSMarch 2024August 2024Allow510NoNo
186067783-(3-FLUOROPHENYL)-5-(4-METHOXYBENZYLTHIO)-4-PHENYL-4H-1,2,4-TRIAZOLE AS AN ANTIMICROBIAL COMPOUNDMarch 2024December 2024Allow911NoNo
18604314THERAPEUTIC COMPOUNDSMarch 2024May 2025Allow1411YesNo
18603405NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAMEMarch 2024April 2025Allow1310NoNo
18602126UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORSMarch 2024March 2025Allow1200NoNo
18600365DNA POLYMERASE THETA INHIBITOR FOR TREATMENT OF CANCERMarch 2024June 2024Allow300YesNo
18598033METHOD FOR SEPARATING FLAVOKAWAIN AND KAVALACTONE, KAVALACTONE, AND MICROENCAPSULATED KAVALACTONEMarch 2024September 2024Allow610NoNo
18595842PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOFMarch 2024May 2025Abandon1410NoNo
18593497BCL-2 InhibitorMarch 2024February 2025Abandon1110NoNo
18589461PRMT5 INHIBITING COMPOUNDS AND USES THEREOFFebruary 2024March 2025Allow1211YesNo
18586920Pleiotropic Pathway Modifier Compounds and Method of Treating DiseasesFebruary 2024September 2024Allow711YesNo
18583627SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAMEFebruary 2024April 2025Allow1411NoNo
18443447METHODS AND COMPOSITIONS FOR MAINTAINING OPIOID EFFICACY IN THE TREATMENT OF PAINFebruary 2024April 2025Allow1420YesNo
18442788PYRROLO[2,3-C][2,6]NAPHTHYRIDINE-8-CARBOXYLIC ACIDS AS CK2 INHIBITORSFebruary 2024July 2024Allow510NoNo
18442417NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATESFebruary 2024February 2025Abandon1211NoNo
18440576POLYMERASE INHIBITORS AND RELATED COMPOSITIONS AND METHODSFebruary 2024December 2024Allow1100NoNo
18440563SPRAY-DRIED DISPERSIONS, FORMULATIONS, AND POLYMORPHS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDEFebruary 2024December 2024Allow1010NoNo
184377024-PHENYLPIPERIDINES, THEIR PREPARATION AND USEFebruary 2024March 2025Allow1310NoNo
18436396SELECTIVE HYDROGENATION CATALYST OF A,B-UNSATURATED KETONE USING ELECTRONICALLY WEAKLY COUPLED 4,4'-DIVINYLAZOARYLENE-BRIDGED DIRUTHENIUM COMPLEX BEARING TWO Ru(CO)(2-MERCAPTOPYRIDINE)(PiPr3)2 MOIETIESFebruary 2024May 2024Allow300NoNo
18435998PLATINUM COMPLEX, ITS PREPARATION AND THERAPEUTIC USEFebruary 2024February 2025Allow1210NoNo
18434637IMIDAZO[1,5-a]PYRIDO[4,3-e]PYRAZINES AS CK2 INHIBITORSFebruary 2024August 2024Allow710NoNo
18433717COMPOUNDS, COMPOSITIONS AND METHODSFebruary 2024December 2024Allow1120YesNo
18433879NOVEL DRP-1 INHIBITORS AS THERAPEUTIC AGENTSFebruary 2024October 2024Allow911NoNo
18428327METHYL 4-((5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)METHYL)BENZOATE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024May 2024Allow400NoNo
18428286METHYL 4-((5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)METHYL)BENZOATE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024June 2024Allow400NoNo
18426321PROTEOLYSIS-TARGETING CHIMERA MOLECULE AND PREPARATION METHOD AND USE THEREOFJanuary 2024January 2025Allow1210NoNo
18424580HETEROCYCLIC GLP-1 AGONISTSJanuary 2024December 2024Allow1020NoNo
18423156CARDIAC SARCOMERE INHIBITORSJanuary 2024December 2024Allow1110NoNo
18422922FORMULATION PRODUCTION PROCESSJanuary 2024August 2024Allow710YesNo
18421117SIRTUIN MODULATING COMPOUNDS AND APPLICATIONS THEREOFJanuary 2024September 2024Allow800YesNo
18421849SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALTJanuary 2024June 2025Allow1701NoNo
18420478ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOFJanuary 2024February 2025Abandon1310NoNo
18420099Stable Pharmaceutical Compositions of ApixabanJanuary 2024September 2024Allow810NoNo
18418168PYRAZOLO[1,5-C]PYRIDO[3,4-E]PYRIMIDINES AS CK2 INHIBITORSJanuary 2024September 2024Allow810NoNo
18416455DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOFJanuary 2024July 2024Allow610NoNo
18416668COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALT CANCERJanuary 2024June 2025Allow1620YesNo
18416748TREATMENT OF CIRCADIAN RHYTHM DISORDERSJanuary 2024September 2024Allow800NoNo
18416734TREATMENT OF CIRCADIAN RHYTHM DISORDERSJanuary 2024October 2024Allow900YesNo
18414924N'-(2-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024August 2024Allow710NoNo
18414737N'-(2-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024September 2024Allow810NoNo
18414429PYRAZOLO[4,3-C][2,6]NAPHTHYRIDINES AS CK2 INHIBITORSJanuary 2024April 2024Allow310NoNo
18412741SELECTIVE HYPOXIA INDUCIBLE FACTOR PROLYL-HYDROXYLASE INHIBITORSJanuary 2024June 2024Allow500NoNo
18412308OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVEJanuary 2024November 2024Allow1001NoNo
18409989PYRIDO[4,3-e]PYRROLO[1,2-a]PYRIMIDINE AS CK2 INHIBITORSJanuary 2024April 2024Allow300YesNo
18407001IMIDAZO[1,2-C]PYRIDO[3,4-E]PYRIMIDINE-3-CARBOXYLIC ACIDS AS CK2 INHIBITORSJanuary 2024March 2024Allow200YesNo
18406455COMPOSITIONS AND METHODS FOR TREATING EYES AND METHODS OF PREPARATIONJanuary 2024May 2025Abandon1701NoNo
183998612-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOFDecember 2023March 2025Allow1410YesNo
183961982-(1-(3-(DIMETHYLAMINO)PROPYL)-4,5-DIPHENYL-1H-IMIDAZOL-2-YL)PYRIDIN-3-OL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDDecember 2023February 2024Allow200NoNo
18395979METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHANDecember 2023March 2025Allow1410NoNo
18394421ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7)December 2023August 2024Allow700NoNo
183949773,5-DINITRO-N-(PYRIMIDIN-2-YLCARBAMOTHIOYL)BENZAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)December 2023March 2024Allow300NoNo
183945343,5-DINITRO-N-(PYRIMIDIN-2-YLCARBAMOTHIOYL)BENZAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)December 2023May 2024Allow400NoNo
18394610(E)-2-(3-CYANO-4-ISOBUTOXYPHENYL)-N'-(SUBSTITUTED BENZYLIDENE)-4-METHYLTHIAZOLE-5-CARBOHYDRAZIDES AS ANTI-TUBERCULAR AGENTSDecember 2023July 2024Allow700YesNo
18392204INHIBITORS OF KINASE NETWORKS AND USES THEREOFDecember 2023March 2025Allow1511NoNo
18392193SUBLINGUAL PHENTERMINE SPRAY COMPOSITIONS AND DAY-NIGHT APPETITE SUPPRESSION AND WEIGHT LOSS REGIMEN USING SAMEDecember 2023March 2025Allow1510NoNo
18391039PYRAZOLO[4,3-C][1,6]NAPHTHYRIDINES AS CK2 INHIBITORSDecember 2023February 2024Allow200YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1621.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
202
Examiner Affirmed
147
(72.8%)
Examiner Reversed
55
(27.2%)
Reversal Percentile
22.7%
Lower than average

What This Means

With a 27.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
1197
Allowed After Appeal Filing
385
(32.2%)
Not Allowed After Appeal Filing
812
(67.8%)
Filing Benefit Percentile
47.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 32.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1621 - Prosecution Statistics Summary

Executive Summary

Art Unit 1621 is part of Group 1620 in Technology Center 1600. This art unit has examined 21,724 patent applications in our dataset, with an overall allowance rate of 72.9%. Applications typically reach final disposition in approximately 24 months.

Comparative Analysis

Art Unit 1621's allowance rate of 72.9% places it in the 34% percentile among all USPTO art units. This art unit has a below-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1621 receive an average of 1.39 office actions before reaching final disposition (in the 18% percentile). The median prosecution time is 24 months (in the 76% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.